Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study

Continuous infusion of beta-lactam antibiotics has emerged as an alternative for the treatment of sepsis because of the favourable pharmacokinetics of continuous infusion. This study aimed to evaluate the survival benefits of continuous vs. intermittent infusion of piperacillin-tazobactam in critica...

Full description

Saved in:
Bibliographic Details
Published in:Antibiotics (Basel) 2022-10, Vol.11 (11), p.1508
Main Authors: Hyun, Dong-gon, Seo, Jarim, Lee, Su Yeon, Ahn, Jee Hwan, Hong, Sang-Bum, Lim, Chae-Man, Koh, Younsuck, Huh, Jin Won
Format: Article
Language:English
Subjects:
Amides
Antibiotics
Antimicrobial agents
Bacteria
Beta lactam antibiotics
Beta lactamases
Blood
Care and treatment
Clinical outcomes
Criteria
critical care
Gram-positive bacteria
Hospital patients
Infection
Infections
intensive care unit
intravenous infusion
Meta-analysis
Mortality
Pathogens
Patient outcomes
Patients
Penicillin
Pharmacokinetics
Piperacillin
Piperacillin-tazobactam
pneumonia
Sepsis
Tazobactam
Ventilators
β-Lactam antibiotics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Continuous infusion of beta-lactam antibiotics has emerged as an alternative for the treatment of sepsis because of the favourable pharmacokinetics of continuous infusion. This study aimed to evaluate the survival benefits of continuous vs. intermittent infusion of piperacillin-tazobactam in critically ill patients with sepsis. We retrospectively conducted a single-centre study of continuous infusion vs. intermittent infusion of piperacillin-tazobactam for adult patients who met the Sepsis-3 criteria and were treated at a medical ICU within 48 h after hospitalisation between 1 May 2018 and 30 April 2020. The primary outcome was mortality at 28 days. A total of 157 patients (47 in the continuous group and 110 in the intermittent group) met the inclusion criteria for evaluation. The 28-day mortality rates were 12.8% in the continuous group and 27.3% in the intermittent group (p = 0.07). However, after adjustment for potential covariables, patients in the continuous group (12.8%) showed significantly lower mortality at 28 days than those in the intermittent group (27.3%; adjusted hazard ratio (HR), 0.31; 95% confidence interval (CI), 0.13–0.79; p = 0.013). In sepsis patients, continuous infusion of piperacillin-tazobactam may confer a benefit regarding the avoidance of mortality at 28 days compared with intermittent infusion.
ISSN:2079-6382
2079-6382
DOI:10.3390/antibiotics11111508